Guerbet SA (0ELV.L)

37,40 +1,55 (+4,32%) In data: 11:06AM BST. Mercato aperto.

Guerbet SA

15, rue des Vanesses
Zone Paris Nord II
Villepinte 93420
France
33 1 45 91 50 00
https://www.guerbet.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 2.920

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. David Hale	CEO, MD & GM	998,04k	N/D	1968
Mr. Jerome Estampes	CFO and Senior VP of Business Development & Licensing	N/D	N/D	N/D
Ms. Sarah Dayre	Senior VP of Technical Operations & Interim Chief Pharmacist	N/D	N/D	N/D
Ms. Charlotte Bamiere	Director of Legal Affairs	N/D	N/D	N/D
Christine Allard	Senior Vice President of Public Affairs & Corporate Communications	N/D	N/D	N/D
Eva Ohlsson	Senior Vice President of Human Resources	N/D	N/D	N/D
Mr. Jean-Francois Blanc	Senior Vice President of Interventional Imaging	N/D	N/D	N/D
Mr. Francois Nicolas	Senior VP of R&D, R&I and Chief Digital Officer	N/D	N/D	1971
Ms. Valérie Brissart	Senior Vice President of Diagnostic Imaging	N/D	N/D	N/D
Mr. Mathieu Elie	Senior Vice President of Commercial Operations - Asia-Pacific	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.

Governance aziendale

L'ISS Governance QualityScore di Guerbet SA al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 6; diritti degli azionisti: 7; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.